DK2146779T3 - Sulfonylamid-derivater til behandling af unormal cellevækst. - Google Patents

Sulfonylamid-derivater til behandling af unormal cellevækst. Download PDF

Info

Publication number
DK2146779T3
DK2146779T3 DK08719431.2T DK08719431T DK2146779T3 DK 2146779 T3 DK2146779 T3 DK 2146779T3 DK 08719431 T DK08719431 T DK 08719431T DK 2146779 T3 DK2146779 T3 DK 2146779T3
Authority
DK
Denmark
Prior art keywords
alkyl
cancer
methyl
group
amino
Prior art date
Application number
DK08719431.2T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Christopher Lowell Autry
Samit Kumar Bhattacharya
Kevin Daniel Freeman-Cook
Matthew Merrill Hayward
Catherine Angela Hulford
Kendra Louise Nelson
Jun Xiao
Xumiao Zhao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK2146779T3 publication Critical patent/DK2146779T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (24)

  1. (a) Sammensætning ifølge formel I:
    i eller et farmaceutisk acceptabelt salt deraf; hvorved A er en ring-enhed, som er udvalgt fra gruppen, som består af et: (a) 4- til 7-element carboclyl, (b) 4- til 7-element heterocyclyl, (c) phenyl, og (d) 5- til 6-element heteroaryl-ring, idet hvert af 4- til 7-element carbocyclyl og 4- til 7-element heterocyclyl i A-gruppen eventuelt kan indeholde én eller to olefiniske bindinger; og hvorved et eller to kulstof-ringatomer i hvert af 4- til 7-element carbocyclyl og 4- til 7-element heterocyclyl i A-gruppen uafhængigt eventuelt kan erstattes af ent eller to enheder, der uafhængigt vælges ud fra gruppen, som består af -C(O)-, -C(S)- og -C(=NR4)-; B er phenyl eller et 5- til 6-element heteroaryl; K er CH, C(NH2) eller N; Hvert R1 er uafhængigt valgt ud fra gruppen, der består af -H, halo, -CF3, -CN, -N02, -NR7R8, -NR7R8)(=CR9), -CR7(NR7R8)(=NR7 ), - NR7C(NR7C(0)R9, -C(0)R9,-C(0)C(0)R9, -C(0)OR10, -0C(0)R9, -or10, -OC(0)OR10, -S(0)jRn, -S(0)(=NR7)R8, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Ci0)cycloalkyl, -(Cs-Cio)cycloalkenyl, -(Ce-Cio)bicycloalkyl, -(C6-Ci0)bicycloalkenyl, -(Ci-C9)heterocycloalkyl, -(C4- C9)heterocycloalkenyl, -(Ce-C^heterocycloalkyl, -(C6- C9)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl; og hvorved hvert af de foregående -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C3-Ci0)cycloalkyl, -(C5-C io)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl og -(Ci-Cg)heteroaryl enheder af R1 i givet fald uafhængigt er-stattes af én, to eller tre R grupper; R2 og R3 er hver uafhængigt udvalgt fra gruppen, som består af -H,-halo, -OR10, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl og -(Ci-C9)heteroaryl; og hvorved hvert af de foregående -(Cr C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cl0)cycloalkyl, -(C5-Cio)cykloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl og -(Ci-Cg)heteroaryl enheder i R2 og R3 i givet fald substitueres af én, to eller tre R grupper; R4 og R5 er hver uafhængigt udvalgt fra gruppen, som består af -H,-NR7R8-(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Ci0)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl og -(Ci-C9)heteroaryl; og hvorved hvert af de foregående (Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Ci0)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl og -(Ci-C9)heteroaryl enheder i R4 og R5 i givet fald substitueres af én, to eller tre R12 grupper; R6 er udvalgt fra gruppen, som består af -halo, -NR7R8, -OR10, -C(0)R9, -C02R10, -CONR7R8, -S(0)jRu, -NR7CONR7R8, og -NR8S02Rn, -N02, -CN, -CF3, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C2-C6)perfluoralkyl, -(C2-C6)perfluoralkynyl, -(C3-C7)cycloalkyl, -(Cs-Ciojcycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(Ci-C9)heterocyclyl, -(Ci- Cio)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(Cg- C9)heterobicyckloalkenyl, -(C6-Cio)aryl, -(Ci-Cg)heteroaryl, -(Cg- Cio)perfluoraryl, og -(Ci-C9)perfluorheteroaryl; og hvorved hver af -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-C7)cycloalkyl, -(C5- Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(Cr C9)heterocyclyl, -(Ci-Cio)heterocycloalkenyl, -(C6-cC9)heterol-enheder af R6-grupper er eventuelt substitueret af én, to eller tre R12-grupper; R7 og R8 er hver uafhængigt udvalgt fra gruppen, som består af -H, -OR10, -S(0)jRn, -NO2, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkyl, -(C6-Cio)bicycloalkyl, -(Ce-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, -(C6-C10)aryl og -(Cl-C9)heteroaryl; og hvorved hvert af de foregående -(Ci-C6)alkyl, -(C2-Ce)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Ci0)aryl og -(Cr C9)heteroaryl-enheder af R og R i givet fald substitueres af én, to eller tre R12 -grupper; Hver R9 er uafhængigt valgt fra gruppen, der består af -H, -Halo, -NR13R14, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Ci0)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C6)heteroaryl; og hvorved hvert af de foregående (Ci-Ce)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl enheder i R9 i gi-vet fald substitueres af een, to eller tre R grupper; Hver R10 er uafhængigt valgt fra gruppen, som består af -H, -(Ci-Cf,), -(C2-Ce)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6- C9)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl; og hvorved hvert af de foregående -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl-enheder i R10 i givet fald substitueres af én, to eller tre R12-grupper. Hver R11 er uafhængigt valgt fra gruppen som består af -H, -NR13R14, -C(0)R13, -CF3, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Ci0)cycloalkenyl, -(Ce-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-Cg)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cg)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl; og hvorved Hver af de foregående (Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(Cs-Cmjcycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroarylenheder i R11 i givet fald substitueres af én, to eller tre R12-grupper. Hver R12 er uafhængigt valgt fra gruppen, som består af -H, -C(0)R13, -0C(0)R13, -0C(0)0R13, -C(0)NR13R14, -NR13C(0)NR13R14, -NR13R14, -(NR13R14)(=NR13), -NR13C(NR13R14)(=N-C(0)R14, -NR13S(0)jR13, - S(0)jR13, -CF3 , -CN, -(CrC6)alkyl, -(C2-C6)alkenyl -(C2-C6)alkenyl, -(C2-Ce)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(Ce- Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(Ce- C9)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl; og hvorved hver af de foregående -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(Cs-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, -(C6-Cio)aryl, og -(Ci-C9)heteroaryl i R12 i givet fald substitueres af én, to eller tre grupper, som er udvalgt fra gruppe, der består af -halo, -CF3, -CN, -N02, -OH, -0((Ci-C6)alkyl), -C(0)R15, -C(0)NR15R16, -S(0)jR15, og S(0)jNR15R16, -(C3-Cio)cycloalkyl, -(C2-C9)heterocycloalkyl, -SH, -S((CrC6)alkyl), -NH2, -NHtfCrQdalkyl og -NKQ-CeJalkyltø R13 og R14 er hver uafhængigt udvalgt fra gruppen, som består af -H, -NR15C(0)R16, -CF3, -CN, -S(0)jR15, -(CrC6)alkyl, -(C2-C6)alkenyl, -(C2-Celalkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(Ce- Cio)bicycloalkyl, -(Ce-Ciolbicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6- C9)heterobicycloalkenyl, -(Ce-Cgjaryl, og -(Ci-C9)heteroaryl; og hvorved hvert af de foregående -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Ci0)cycloalkenyl, -(C6-Ci0)bicycloalkyl, -(C6- Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, -(C6-Cg)aryl, og -(Ci-C9)heteroaryl i R13 og R14 i givet fald uafhængigt substitueres af én, to eller tre grupper, som er udvalgt fra gruppen, der består af -halo, -CF3, -CN, -N02, -OH, -0((Ci-C6)alkyl, -C(0)((Ci-C6)alkyl), -(C3-Cio)cycloalkyl, -(C2-C9)heterocycloalkyl, -SH, -S((Ci-C6)alkyl), -NH2, -NH((Ci-C6)alkyl) og -N((Ci-C6)alkyl)2; R15 og R16 er hver uafhængigt valgt fra gruppen, der består af -H, -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2- C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, og -(Ci-C9)heteroaryl; og hvorved hver af de foregående -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, og -(Ci-Cg)heteroaryl i R15 og R16 i givet fald uafhængigt substitueres af én eller to eller tre grupper, der består af -halo, -CF3, -CN, -NO2, -OH, -0((Ci-C6)alkyl), -C(0)((CrC6)alkyl, -(C3-C10)cycloalkyl, - (C2- C9)heterocycloalkyl, -NH2, -NH((Ci-C6)alkyl) og -N((Ci-C6)alkyl)2; hvorved eet eller to carbonring-atomer i hver af de førnævnte -(Ci-C6)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl, -(C3-Ci0)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(C6-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(Οβ- C9)heterobicycloalkenyl, i R1 til R14 grupperne i givet fald og uafhængigt kan erstattes med -(CO)- eller -C(S)-; hvorved to grupper, som er fastgjort til samme tetravalente carbonatom i hver af de førnævnte -(Ci-Cejalkyl, -(C2-C6)alkenyl, -(Q-Cejalkynyl, -(C3- Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C6-Cio)bicycloalkyl, -(Ce-Cio)bicycloalkenyl, -(C2-C9)heterocycloalkyl, -(C4-C9)heterocycloalkenyl, -(C6-C9)heterobicycloalkyl, -(C6-C9)heterobicycloalkenyl, i R1 til R14 grupperne i givet fald kan forenes, så der dannes et ringsystem, der er udvalgt fra gruppen, som består af et -(C3-Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-Cgjheterocycloalkyl, -(C4-C9)heterocycloalkenyl, og hvorved J er et heltal fra 0 til 2; n er et heltal fra 1 til 3; og m er et heltal fra 0 til 3: hvorved alkyl, alkenyl, alkynyl, cycloalkyl, cycloal-kenyl, 4- til 7-element carbocyclyl, (C6-Cio)aryl, (Ci-Cg)heteoaryl, 5- til 6-element heteoaryl-ring, (C1 -Cgjheterocycloalkyl, (C4-Cg)heterocycloalkenyl og 4- til 7-element heterocyclylgrupper hver i givet fald kan substitueres med 1, 2 eller 3 fluoro, chloro, trifluoromethyl, -(Ci-C6)alkoxy, -(C6-Cio)aryloxy, trifluoromethoxy, difluoromethoxy eller -(Ci-C6)alkyl substituent(er).
  2. 2. Sammensætning ifølge krav 1, hvorved A er et phenyl.
  3. 3. Sammensætning ifølge krav 1, hvorved A er et 5- til 6-leddet heteroaryl.
  4. 4. Sammensætning ifølge et hvilket som helst af de foregående krav, hvorved hver R1 er uafhængigt udvalgt fra gruppen, der består af -H, halo, -CF3, -CN, -NO2, -NR7R8, -NR7R8)(=CR9), -CR7(NR7R8)(=NR7 ), -NR7C(NR7C(0)R9, -C(0)R9,-C(0)C(0)R9, -C(0)OR10, -0C(0)R9, -OR10, -OC(0)OR10, -S(0)jRn og -S(0)(=NR7)R8.
  5. 5. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvorved R1 er -C(0)R9.
  6. 6. Sammensætning ifølge krav 5, hvorved R1 er -C(0)R9, og R9 er udvalgt fra gruppen, som består af -NR13R14, -(Ci-C6)alkyl og -(C3-Cio)cycloalkyl; hvorved hver af -(Ci-C6)alkyl, og -(C3-Cio)cycloalkyl i R9 -gruppen i givet fald substitueres af én til tre R12-grupper; og hvorved to grupper, der er fastgjort til samme tetravalente carbon-atom i — (Ci-Cejalkylet og -(C3-Cio)cycloalkylet i R9, i givet fald kan sammenføjes, så der dannes et ringsystem, der er udvalgt fra gruppen, som består af et -(C3- Cio)cycloalkyl, -(C5-Cio)cycloalkenyl, -(C2-C9)heterocycloalkyl, og -(C4-C9)heterocycloalkenyl.
  7. 7. Sammensætning ifølge krav 6, hvorved R1 er -C(0)R9, og R9 er -NR13R14.
  8. 8. Sammensætning ifølge krav 7, hvorved R1 er -C(0)R9, R9 er -NR13R14, og R13 og R14 er hver uafhængigt udvalgt fra gruppen, som består af -H og -(Ci-C6)alkyl; og hvorved -(Ci-C6)alkyl i R13 og R14 -grupperne i givet fald uafhængigt substitueres af én til tre grupper, der er udvalgt fra gruppen, som består af -halo, -CF3, -CN, -NO2, -OH, -0((Ci-C6)alkyl), -C(0)((Ci-C6)alkyl, -(C3-Ci0)cycloalkyl, - (C2- C9)heterocycloalkyl, -SH, S((Ci-C6)alkyl), -NH2, -N((Ci-C6)alkyl) og -N((Cr C6)alkyl)2.
  9. 9. Sammensætning ifølge et hvilket som helst af de foregående krav, hvorved R2 og R3 er hver uafhængigt udvalgt fra gruppen, som består af -H, -halo, og -OR10.
  10. 10. Sammensætning ifølge et hvilket som helst af kravene 1 til 8, hvorved R og R er hver uafhængigt udvalgt fra gruppen, der består af -H, -(Ci-C6)alkyl, -(C2-C6)alkenyl og -(C2-C6)alkynyl; og hvorved hver af de foregående -(Ci-C6)alkyl, -(C2-C6)alkynyl-enheder i R2 og R3 i givet fald uafhængigt substitueres af én til tre R12 grupper.
  11. 11. Sammensætning ifølge et hvilket som helst af de foregående krav, hvorved R4 og R5 er hver uafhængigt udvalgt fra gruppen, som består af -H, -(Ci-C6)alkyl, -(C2-C6)alkenyl og -(C2-C6)alkynyl; og hvorved hver af de foregående -(Ci-C6)alkyl, -(C2-C6)(alkenyl og -(C2-C6)alkynyl-enheder i R4 og R5 i givet fald uafhængigt substitueres af én til tre R12 grupper.
  12. 12. Sammensætning ifølge et hvilket som helst af de foregående krav, hvorved R6 er -CF3, K er CH, m er 1, og n er 1.
  13. 13. Sammensætning ifølge krav 1, hvorved enheden
    repræsenterer en enhed, der er udvalgt fra gruppen, som består af:
  14. 14. Sammensætning ifølge krav 1, og som er udvalgt fra gruppen, der består af (R)-N-(3-((2-(4-(l-aminoethyl)phenylamino)-5-(trifluoromethyl)pyrimidin-4- ylamino)pyridine-2-yl)-N-methylmethan-sulfonamid; N-(3-((2-(4-(aminomethyl)phenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino) Methyl)pyridine-2-yl)-N-methylmethan-sulfonamid; N-[4-[{ {2-[methyl(methylsufonyl)amino]pyridine-3-yl}methyl)amino]-5-(trifluo-romethyl)pyrimidin-2-yl} amino)benzyl] acetamid; N-(3((2-(4-(hydroxymethyl)phenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridine-2-yl)-N-methylmethan-sulfonamid; og N-(3-((2-(4-(chloromethyl)phenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridine-2-yl)-N-methylmethan-sulfonamid; eller et farmaceutisk acceptabelt salt deraf.
  15. 15. Sammensætning ifølge krav 1, og som er udvalgt fra gruppen, der består af N-(3-((2-(4-(( 1,3-dihydroxypropan-2-ylamino)phenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridine-2-yl)-N-methylmethan-sulfonamid; eller et acceptabelt salt deraf; Tert-butyl 3-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5 - (trifluoromethyl)pyrimidin-2-yl} amino)benzoat; 3-( {4- [({2- [methyl(methylsulfonyl)amino]pyridin-3-yl }methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl} amino)benzoesyre; N-cyclopropyl-3-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamid; og N-(3-((2-(4-(l-hydroxyetyl)phenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)-N-methylmethansulfonamid; eller et farmaceutisk acceptabelt salt deraf.
  16. 16. Sammensætning ifølge krav 1, og som er udvalgt fra gruppen, der består af 2- fluoro-4-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yllamino)benzamid; 3- fluoro-4-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yllamino)benzamid; og N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-( trifluoromethyl)pyrimidin-2-yllamino)benzamid; eller et farmaceutisk acceptabelt salt deraf.
  17. 17. Sammensætning ifølge krav 1, og som er udvalgt fra gruppen, som består af 2-fbioro-4-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-( trifluoromethyl)pyrimidin-2-yllamino)benzamid format; 3-fluoro-4-({4-[({2-[methyl(methylsulfonyl)amino]pyridin-3-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamid format; og N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-( trifluoromethyl)pyrimidin-2-yl}amino)benzamid hydrochlorid; 18. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino] -5-( trifluoromethyl)pyrimidin-2-yl}amino)benzamid ifølge formlen:
    eller et farmaceutisk acceptabelt salt deraf. 19. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-( trifluoromethyl)pyrimidin-2-yl}amino)benzamid hydrochlorid.
  18. 20. Farmaceutisk sammensætning, omfattende en sammensætning eller et salt ifølge et hvilket som helst af kravene 1 til 19 og et farmaceutisk acceptabelt hjælpestof, fortynding smiddel, bærestof eller excipiens.
  19. 21. Sammensætning eller salt ifølge et hvilket som helst af kravene 1 til 19 til anvendelse ved behandling af cancer i et pattedyr.
  20. 22. Sammensætning til anvendelse ifølge krav 21, hvorved canceren er udvalgt fra gruppen, som består af lungekræft, knoglekræft, bug spytkirtelkræft, hudkræft, kræft i hovedet eller nakken, cutan eller intraocular melanom, livmoderkræft, æggestokskræft, endetarmskræft, kræft i endetarmsåbningen, mavekræft, tyktarmskræft, brystkræft, carcinom i æggelederne, carcinom i endometrium, carcinom i halsen, carcinomi vagina, carcinom i vulva, Hodgkins sygdom, cancer i spiserøret, cancer i tyndtarmen, cancer i det indokrine system, cancer i skjoldbruskkirtlen, cancer i biskjoldbruskkirtlen, cancer i binyrerne, sarkom i blødt væv, cancer i urinrørskræft, cancer i penis, prostatakræft, kronisk eller akut leukæmi, lymfekræft, kræft i blæren, kræft i nyre eller urinleder, nyrecellecarcinom, carcinom i nyrebækkenet, svulster i centralnervesystemet (CNS), primært CNS-lymphom, rygradstumorer, hjernestamme-tumorer, hypofyse-adenom, eller en kombination af én eller flere af de foregående kræftformer.
  21. 23. Anvendelse af en sammensætning eller et salt ifølge et hvilket som helst af kravene 1 til 19 med henblik på fremstilling af et medikament til behandling afkræft i et pat tedyr.
  22. 24. Anvendelse ifølge krav 23, hvorved canceren er udvalgt fra gruppen, som består af lungekræft, knoglekræft, bugspytkirtelkræft, hudkræft, kræft i hovedet eller nakken, cutan eller intraocular melanom, livmoderkræft, æggestokskræft, endetarmskræft, kræft i endetarmsåbningen, mavekræft, tyktarmskræft, brystkræft, carcinom i æggelederne, carcinom i endometrium, carcinom i halsen, carcinomi vagina, carcinom i vulva, Hodgkins sygdom, cancer i spiserøret, cancer i tyndtarmen, cancer i det indokrine system, cancer i skjoldbruskkirtlen, cancer i biskjoldbruskkirtlen, cancer i binyrerne, sarkom i blødt væv, cancer i urinrørskræft, cancer i penis, prostatakræft, kronisk eller akut leukæmi, lymfekræft, kræft i blæren, kræft i nyre eller urinleder, nyrecellecarcinom, carcinom i nyrebækkenet, svulster i centralnervesystemet (CNS), primært CNS-lymphom, rygradstumorer, hjemestammetumorer, hypofyse-adenom, eller en kombination af én eller flere af de foregående kræftformer.
  23. 25. En kombination af en sammensætning eller salt ifølge et hvilket som helst af kravene til 19, og et kræftbekæmpelsesmiddel, et svulstbekæmpelsesmiddel eller et middel, som er nyttigt ved behandling af unormal cellevækst.
  24. 26. Farmaceutisk sammensætning, omfattende en terapeutisk effektiv mængde af sammensætning eller salt ifølge et hvilket som helst af kravene 1 til 19, et farmaceutisk acceptabelt bærestof og, eventuelt, i det mindste eet yderligere medicinsk eller farmaceutisk middel.
DK08719431.2T 2007-04-18 2008-04-07 Sulfonylamid-derivater til behandling af unormal cellevækst. DK2146779T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91259707P 2007-04-18 2007-04-18
PCT/IB2008/000845 WO2008129380A1 (en) 2007-04-18 2008-04-07 Sulfonyl amide derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
DK2146779T3 true DK2146779T3 (da) 2016-11-28

Family

ID=39646361

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08719431.2T DK2146779T3 (da) 2007-04-18 2008-04-07 Sulfonylamid-derivater til behandling af unormal cellevækst.

Country Status (33)

Country Link
US (12) US7928109B2 (da)
EP (1) EP2146779B1 (da)
JP (1) JP4782239B2 (da)
KR (1) KR101132880B1 (da)
CN (2) CN101678215B (da)
AP (1) AP2009005010A0 (da)
AR (1) AR066125A1 (da)
AU (1) AU2008240359B2 (da)
BR (1) BRPI0810411B8 (da)
CA (1) CA2684447C (da)
CL (1) CL2008001076A1 (da)
CO (1) CO6260093A2 (da)
CU (1) CU23813A3 (da)
DK (1) DK2146779T3 (da)
DO (1) DOP2009000248A (da)
EA (1) EA016679B1 (da)
EC (1) ECSP099694A (da)
ES (1) ES2593486T3 (da)
GE (1) GEP20125581B (da)
GT (1) GT200900272A (da)
HK (2) HK1200450A1 (da)
IL (3) IL201468A (da)
MA (1) MA31319B1 (da)
MX (1) MX2009011090A (da)
NI (1) NI200900190A (da)
NZ (1) NZ580372A (da)
PA (1) PA8777101A1 (da)
PE (1) PE20090434A1 (da)
TN (1) TN2009000428A1 (da)
TW (1) TWI369205B (da)
UA (1) UA97834C2 (da)
UY (1) UY31026A1 (da)
WO (1) WO2008129380A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580372A (en) * 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
JP2011515372A (ja) * 2008-03-20 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリミジン類の位置選択的製造法
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
CN102203080A (zh) * 2008-09-03 2011-09-28 拜尔农作物科学股份公司 作为杀菌剂的杂环取代的苯胺基嘧啶
UY32240A (es) * 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
JP2010111702A (ja) * 2009-02-16 2010-05-20 Tetsuya Nishio 複素環化合物、その製造法および用途
CN101812016B (zh) * 2009-02-23 2013-01-16 浙江海翔药业股份有限公司 一种制备依托昔布中间体-6-甲基烟酸及其酯的方法
EP2261211A1 (en) * 2009-05-20 2010-12-15 Université de Lille 2 Droit et Santé 1,4-dihydropyridine derivatives and their uses
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
TWI500614B (zh) 2009-06-05 2015-09-21 Cephalon Inc １，２，４－***並〔１，５ａ〕吡啶衍生物之製備和用途
JP5539518B2 (ja) * 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
KR101531448B1 (ko) * 2010-06-04 2015-06-24 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서의 아미노피리미딘 유도체
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PL2646448T3 (pl) 2010-11-29 2017-12-29 OSI Pharmaceuticals, LLC Makrocykliczne inhibitory kinazy
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
US9139534B2 (en) 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CN103781780B (zh) * 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
RU2564419C1 (ru) * 2011-07-28 2015-09-27 Целльзом Лимитид Гетероциклические аналоги пиримидина в качестве ингибиторов jak
BR112014006743A8 (pt) 2011-09-21 2018-01-09 Cellzome Ltd composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
CA2850852A1 (en) 2011-10-07 2013-04-11 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
AU2012357038B2 (en) 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CN106166155B (zh) * 2012-03-06 2019-01-18 赛福伦公司 作为alk和fak双重抑制剂的稠合双环2,4-二氨基嘧啶衍生物
BR112014029310A2 (pt) 2012-05-24 2018-06-26 Cellzome Ltd análogos da pirimidina heterocíclica como inibidores da tyk2
NZ721934A (en) * 2014-01-09 2022-04-29 Pfizer Compositions and methods for treatment of abnormal cell growth
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
FI3698790T3 (fi) * 2014-02-07 2023-06-06 Verastem Inc Menetelmiä epänormaalin solukasvun hoitamiseksi
MD20160121A2 (ro) 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
SG10202010389TA (en) 2014-12-16 2020-11-27 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018000288A (es) 2015-06-29 2018-11-09 Verastem Inc Composiciones terapeuticas, combinaciones y metodos de uso.
EP3795553B1 (en) 2015-07-24 2024-05-15 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN105111204B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 吡啶盐类酪氨酸激酶抑制剂、制备方法及其用途
CN105153150B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 一类吡啶盐类jak抑制剂、制备方法及其用途
CN105503860B (zh) * 2015-10-13 2017-03-01 天津小新医药科技有限公司 一类腈基取代的吡啶盐类jak抑制剂、制备方法及其用途
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN106279011A (zh) * 2016-08-16 2017-01-04 成都百事兴科技实业有限公司 一种2,4‑二羟基‑6‑甲基烟酸乙酯的制备方法
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
CA3093742A1 (en) 2018-03-12 2019-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
RU2761825C1 (ru) * 2018-05-07 2021-12-13 Хинова Фармасьютикалс Инк. Соединения дейтерированного дефактиниба и их применение
WO2020006724A1 (zh) * 2018-07-05 2020-01-09 清华大学 一种靶向降解fak蛋白的化合物及其应用
CA3109617A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US20220125788A1 (en) * 2018-12-27 2022-04-28 Hinova Pharmaceuticals Inc. FAK inhibitor and drug combination thereof
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
CN112592318B (zh) * 2020-12-12 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用
CN112624966B (zh) * 2020-12-25 2022-12-23 杭州澳赛诺生物科技有限公司 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法
KR20230117416A (ko) * 2021-01-18 2023-08-08 하이노바 파마슈티컬스 인코포레이티드 아미노피리미딘계 fak 억제제 화합물의 합성 방법
CN113372334B (zh) * 2021-05-25 2022-05-03 贵州医科大学 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用
EP4349339A1 (en) * 2021-05-25 2024-04-10 Hinova Pharmaceuticals Inc. Pharmaceutical composition for treatment of cancer and use thereof
CN114716385B (zh) * 2022-04-08 2024-03-12 北京师范大学 靶向粘着斑激酶的化合物及制备方法和应用
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024071371A1 (ja) * 2022-09-30 2024-04-04 ユビエンス株式会社 複素環式化合物
CN117105916B (zh) * 2023-10-23 2024-01-16 希格生科（深圳）有限公司 苯并呋喃类化合物及其医药用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
ATE159009T1 (de) 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
WO1998002437A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT923585E (pt) 1996-07-18 2002-08-30 Pfizer Inibidores a base de fosfinato de metaloproteases de matriz
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
ES2224277T3 (es) 1997-01-06 2005-03-01 Pfizer Inc. Derivados de sulfonas ciclicas.
DK0977733T3 (da) 1997-02-03 2003-11-24 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
EA002490B1 (ru) 1997-08-08 2002-06-27 Пфайзер Продактс Инк. Производные арилоксиарилсульфониламиногидроксамовой кислоты
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
IT1302431B1 (it) * 1998-08-12 2000-09-05 Alasi Di Arcieri Franco & C S Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole
ES2213985T3 (es) 1998-11-05 2004-09-01 Pfizer Products Inc. Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
EP1282606B1 (en) 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replication inhibiting pyrimidines and triazines
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6853233B1 (en) * 2000-09-13 2005-02-08 Infineon Technologies Ag Level-shifting circuitry having “high” output impedance during disable mode
IT1319686B1 (it) 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
CN102250071A (zh) 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
PL367130A1 (en) 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7008378B2 (en) * 2002-03-07 2006-03-07 Dean Melanie A Patient conditional diagnosis assessment and symptom tracking system
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) * 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (pl) 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
SE0203820D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab chemical compounds
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
JP2006528640A (ja) 2003-07-22 2006-12-21 ニューロジェン・コーポレーション 置換ピリジン−２−イルアミン類縁体
EP1660458B1 (en) 2003-08-15 2012-01-25 Novartis AG 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ES2276344T3 (es) 2003-09-05 2007-06-16 Pfizer Products Inc. Sintesis selectiva de pirimidinas sustituidas con cf3.
US7363505B2 (en) * 2003-12-03 2008-04-22 Pen-One Inc Security authentication method and system
WO2005111016A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CN1953974A (zh) * 2004-05-14 2007-04-25 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
AU2005252211A1 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP4990766B2 (ja) 2004-07-01 2012-08-01 シンタ ファーマシューティカルズ コーポレーション 二置換型ヘテロアリール化合物
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101039919A (zh) 2004-10-13 2007-09-19 惠氏公司 经n－苯磺酰基取代的苯胺基嘧啶类似物
WO2006053112A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Process for preparing trisubstituted pyrimidine compounds
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8722884B2 (en) 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0620324A2 (pt) 2005-12-21 2011-11-08 Pfizer Prod Inc derivados de pirimidina, composição farmaceutica e uso dos mesmos
NZ580372A (en) * 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer

Also Published As

Publication number Publication date
UA97834C2 (ru) 2012-03-26
US20170327485A1 (en) 2017-11-16
CN101678215A (zh) 2010-03-24
EA200901250A1 (ru) 2010-04-30
IL260560B (en) 2021-04-29
TW200848050A (en) 2008-12-16
CN103951658A (zh) 2014-07-30
MX2009011090A (es) 2009-11-02
IL232511B (en) 2018-07-31
JP4782239B2 (ja) 2011-09-28
ECSP099694A (es) 2009-11-30
US20090054395A1 (en) 2009-02-26
US20220251066A1 (en) 2022-08-11
EA016679B1 (ru) 2012-06-29
WO2008129380A1 (en) 2008-10-30
CL2008001076A1 (es) 2008-10-24
HK1200450A1 (en) 2015-08-07
KR20090130248A (ko) 2009-12-21
US20170001981A1 (en) 2017-01-05
EP2146779B1 (en) 2016-08-10
AU2008240359B2 (en) 2014-06-26
NZ580372A (en) 2012-01-12
US20110166120A1 (en) 2011-07-07
BRPI0810411B8 (pt) 2021-05-25
IL201468A0 (en) 2010-05-31
CA2684447A1 (en) 2008-10-30
CN101678215B (zh) 2014-10-01
KR101132880B1 (ko) 2012-06-28
CU23813A3 (es) 2012-06-21
UY31026A1 (es) 2008-11-28
US7928109B2 (en) 2011-04-19
PE20090434A1 (es) 2009-04-13
US20240109862A1 (en) 2024-04-04
US8247411B2 (en) 2012-08-21
AP2009005010A0 (en) 2009-10-31
GEP20125581B (en) 2012-07-25
US20130005964A1 (en) 2013-01-03
IL232511A0 (en) 2014-06-30
HK1136985A1 (en) 2010-07-16
IL201468A (en) 2014-06-30
GT200900272A (es) 2010-05-17
AR066125A1 (es) 2009-07-22
AU2008240359A1 (en) 2008-10-30
US20200002310A1 (en) 2020-01-02
CA2684447C (en) 2012-01-24
US10450297B2 (en) 2019-10-22
TN2009000428A1 (fr) 2011-03-31
DOP2009000248A (es) 2009-11-15
US20190047979A1 (en) 2019-02-14
MA31319B1 (fr) 2010-04-01
CN103951658B (zh) 2017-10-13
CU20090175A7 (es) 2011-09-21
BRPI0810411B1 (pt) 2019-09-10
US20140100368A1 (en) 2014-04-10
BRPI0810411A2 (pt) 2014-10-14
US20150080368A1 (en) 2015-03-19
US8440822B2 (en) 2013-05-14
US20160130250A1 (en) 2016-05-12
PA8777101A1 (es) 2008-11-19
NI200900190A (es) 2010-01-27
EP2146779A1 (en) 2010-01-27
TWI369205B (en) 2012-08-01
JP2010524914A (ja) 2010-07-22
CO6260093A2 (es) 2011-03-22
ES2593486T3 (es) 2016-12-09

Similar Documents

Publication Publication Date Title
DK2146779T3 (da) Sulfonylamid-derivater til behandling af unormal cellevækst.
US7235562B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566332A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AU2009238255A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AU2016201820B2 (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
AU2014201847B2 (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth